RESEARCH & DEVELOPMENT

RESEARCH & DEVELOPMENT

PHARMACEUTICAL
AntalGenics uses its more than 15 years of research experience to clinically develop novel therapeutic leads, mainly for the treatment of psoriatic pruritus and psoriatic comorbidities, such as arthritis.
COSMECEUTICAL
AntalGenics centers its projects on more than 15 years of experience on the research of novel targets and molecules to treat chronic painful disorders. Our team has international long proven-track record on pain research, allowing the development of novel and innovative analgesic treatments.

ANTALGENICS OFFERS

Proven-track record in pain research
Specialists in ion channel research and neuronal exocytosis
Full access to University infrastructures
Skilled team in sensory biology
Rich-network of partner research groups
Experts in molecular modeling and in silico screening
A long standing experience in cosmeceutics
PHARMACEUTICAL

AntalGenics’ R&D program focuses on the discovery and development of new molecules to treat chronic painful disorders. Our scientific team has a long-track experience in pain research and applies the most advanced technologies to identify new molecular targets and to understand the underlying disease’s molecular mechanisms.

With this knowledge, AntalGenics is currently developing two new molecular entities to provide precise innovative therapies for psoriatic pruritus and osteoarthritic pain.

COSMECEUTICAL

AntalGenics provides supplementary solutions in the field of dermatology. Our team has a proven track record of bringing new cosmeceutical products to market with the main goal to improve skin care by science.

AntalGenics has built a pipeline of innovative compounds to treat sensitive skin conditions by targeting neurogenic inflammation: AntalGenics is currently focusing its target compounds on mild atopia, dermatitis (contact, seborrheic, allegenic, stress, etc.) and rosacea.

GET TO KNOW MORE